Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures
Nikolai Eroshenko, Taylor Gill, Marianna K. Keaveney, et al.
Nature Biotechnology (2020) Vol. 38, Iss. 7, pp. 789-791
Open Access | Times Cited: 125

Showing 1-25 of 125 citing articles:

Immunological considerations for COVID-19 vaccine strategies
Mangalakumari Jeyanathan, Sam Afkhami, Fiona Smaill, et al.
Nature reviews. Immunology (2020) Vol. 20, Iss. 10, pp. 615-632
Open Access | Times Cited: 1024
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
Shengli Xia, Kai Duan, Yuntao Zhang, et al.
JAMA (2020) Vol. 324, Iss. 10, pp. 951-951
Open Access | Times Cited: 763
Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution
Emmanuel Alakunle, Ugo Moens, Godwin Nchinda, et al.
Viruses (2020) Vol. 12, Iss. 11, pp. 1257-1257
Open Access | Times Cited: 672
Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2
Yufei Xiang, Sham Nambulli, Zhengyun Xiao, et al.
Science (2020) Vol. 370, Iss. 6523, pp. 1479-1484
Open Access | Times Cited: 403
COVID-19 vaccine development: milestones, lessons and prospects
Maochen Li, Han Wang, Lili Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 331
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Qianqian Zhang, Rong Xiang, Shanshan Huo, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 302
Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression
Mary Kathryn Bohn, Alexandra Hall, Lusia Sepiashvili, et al.
Physiology (2020) Vol. 35, Iss. 5, pp. 288-301
Open Access | Times Cited: 251
Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses
Jason T. Ladner, Sierra N. Henson, Annalee S. Boyle, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 1, pp. 100189-100189
Open Access | Times Cited: 176
Antibody Responses in COVID-19: A Review
Mateo Chvatal-Medina, Yorjagis Mendez-Cortina, Pablo Javier Patiño Grajales, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 137
Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
Natalie Yan‐Lin Pang, Alexander Shao‐Rong Pang, Vincent Chow, et al.
Military Medical Research (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 132
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
Yunjiao Zhou, Zezhong Liu, Shibo Li, et al.
Cell Reports (2021) Vol. 34, Iss. 5, pp. 108699-108699
Open Access | Times Cited: 127
Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
Savannah E. Butler, Andrew R. Crowley, Harini Natarajan, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 115
COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds
John P. Moore, Per Johan Klasse
Journal of Virology (2020) Vol. 94, Iss. 17
Open Access | Times Cited: 92
Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19
Kumaragurubaran Karthik, Tuticorin Maragatham Alagesan Senthilkumar, Shanmugasundaram Udhayavel, et al.
Human Vaccines & Immunotherapeutics (2020) Vol. 16, Iss. 12, pp. 3055-3060
Open Access | Times Cited: 85
Stereotypic neutralizing V H antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals
Sang Il Kim, Jinsung Noh, Sujeong Kim, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 578
Open Access | Times Cited: 85
An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2
Takuya Tada, Fan Chen, Jennifer Chen, et al.
Cell Reports (2020) Vol. 33, Iss. 12, pp. 108528-108528
Open Access | Times Cited: 81
Overview of Neutralizing Antibodies and Their Potential in COVID-19
José Javier Morales‐Núñez, José Francisco Muñoz‐Valle, Paola Carolina Torres-Hernández, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1376-1376
Open Access | Times Cited: 67
Glycosylation is a key in SARS-CoV-2 infection
Celso A. Reis, R Tauber, Véronique Blanchard
Journal of Molecular Medicine (2021) Vol. 99, Iss. 8, pp. 1023-1031
Open Access | Times Cited: 66
Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children
Ming‐Ren Chen, Ho‐Chang Kuo, Yann‐Jinn Lee, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 66
SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients
Roberto Gozalbo‐Rovira, Estela Giménez, Víctor Latorre, et al.
Journal of Clinical Virology (2020) Vol. 131, pp. 104611-104611
Open Access | Times Cited: 69
SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia
Wei Chen, Jie Zhang, Xijian Qin, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 130, pp. 110629-110629
Open Access | Times Cited: 66
Brilliant glycans and glycosylation: Seq and ye shall find
Guanwen Gao, Chen Li, Wenguo Fan, et al.
International Journal of Biological Macromolecules (2021) Vol. 189, pp. 279-291
Closed Access | Times Cited: 41
Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors—The Current Status
Narasimha M. Beeraka, Surya Prabha Sadhu, SubbaRao V. Madhunapantula, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 46
Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice
Xianglei Liu, Aleksandra Drelich, Wei Li, et al.
Vaccine (2020) Vol. 38, Iss. 46, pp. 7205-7212
Open Access | Times Cited: 40
Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Ligong Lu, Hui Zhang, Meixiao Zhan, et al.
Science China Life Sciences (2020) Vol. 63, Iss. 12, pp. 1833-1849
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top